Abstract

JACC

Lots of interesting abstracts and cases were submitted for TCTAP 2022. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!

TCTAP A-040

Big Endothelin-1 and Five-Year Long-term All-cause Death in Patients With Coronary Artery Disease and Prediabetes or Diabetes after Percutaneous Coronary Intervention

By Na Xu, Sida Jia, Deshan Yuan, Jingjing Xu, Huanhuan Wang, Ying Song, Lijian Gao, Zhan Gao, Runlin Gao, Bo Xu, Jinqing Yuan

Presenter

Na Xu

Authors

Na Xu1, Sida Jia1, Deshan Yuan1, Jingjing Xu1, Huanhuan Wang1, Ying Song1, Lijian Gao1, Zhan Gao1, Runlin Gao1, Bo Xu1, Jinqing Yuan1

Affiliation

Fuwai Hospital, China1
View Study Report
TCTAP A-040
Diabetes

Big Endothelin-1 and Five-Year Long-term All-cause Death in Patients With Coronary Artery Disease and Prediabetes or Diabetes after Percutaneous Coronary Intervention

Na Xu1, Sida Jia1, Deshan Yuan1, Jingjing Xu1, Huanhuan Wang1, Ying Song1, Lijian Gao1, Zhan Gao1, Runlin Gao1, Bo Xu1, Jinqing Yuan1

Fuwai Hospital, China1

Background

Background: The aim of the present study is to examine the effects of big endothelin-1(big ET-1) on long-term all-cause death in patients with coronary artery disease (CAD) and different glucose metabolism status.

Methods

Methods: In this study, we consecutively enrolled 8,550 patients from January 2013 to December 2013. Patients were categorized according to both status of glucose metabolism status [Diabetes Mellitus (DM), Pre-Diabetes (Pre-DM), Normoglycemia (NG)] and big ET-1 levels. All subjects were followed up for the occurrence of the all-cause death.

Results

Results: During a median of 5.1-year follow-up periods, 301 all-cause deaths occurred. Elevated big ET-1 was significantly associated with long-term all-cause death (adjusted hazard ratio (HR): 2.230, 95% confidence interval (CI) 1.629-3.051; p < 0.001). Similarly, patients with DM, but not Pre-DM, had increased risk of all-cause death compared with NG group (p < 0.05). When patients were categorized by both status of glucose metabolism and big ET-1 levels, high big ET-1 were associated with significantly higher risk of all-cause death in Pre-DM (adjusted HR: 2.442, 95% CI 1.039-5.740; p = 0.041) and DM (adjusted HR: 3.162, 95% CI 1.376–7.269; p = 0.007). The Kaplan-Meier curve indicated that DM patients with the highest big ET-1 levels were associated with the greatest risk of all-cause death (p < 0.05).

Conclusion

Conclusions: The present data indicated that baseline big ET-1 levels were independently associated with the long-term all-cause death in DM and Pre-DM patients with CAD undergoing PCI, suggesting that big ET-1 may be a valuable marker in patients with impaired glucose metabolism.

Leave Comments